Barbara Finck
Director/Board Member at FORTE BIOSCIENCES, INC.
Net worth: 576 $ as of 2024-06-29
Profile
Barbara K.
Finck is an Independent Director at Forte Biosciences, Inc. since 2022 and a Director at Comera Life Sciences, Inc. since 2001.
She previously worked as a Medical Director at Immunex Corp.
from 1996 to 2001, a Director at Comera Life Sciences Holdings, Inc., a Manager-Clinical Program at ALZA Corp.
from 1994 to 1996, a Vice President-Clinical Development at Protein Design Labs, Inc. from 2003 to 2006, a Chief Medical Officer & Senior VP-Research at Osprey Pharmaceuticals USA, Inc. from 2007 to 2010, a Vice President-Clinical Development at EOS Biotechnology, Inc. from 2001 to 2003, and an Assistant Professor at The University of California, San Francisco from 1992 to 1994.
She also held positions at PDL BioPharma, Inc., Osprey Pharmaceuticals Ltd., NKT Therapeutics, Inc., and Coherus BioSciences, Inc. Dr. Finck completed her undergraduate degree at the University of California, Santa Barbara and obtained her doctorate from UCSF School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-01-03 | 23,033 ( 0.07% ) | 576 $ | 2024-06-29 | |
FORTE BIOSCIENCES INC.
-.--% | 2024-04-18 | 0 ( -.--% ) | - $ | 2024-06-29 |
Barbara Finck active positions
| Companies | Position | Start |
|---|---|---|
| FORTE BIOSCIENCES, INC. | Director/Board Member | 2022-03-15 |
Comera Life Sciences, Inc.
 Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Director/Board Member | 2001-02-28 |
Former positions of Barbara Finck
| Companies | Position | End |
|---|---|---|
| COMERA LIFE SCIENCES HOLDINGS, INC. | Director/Board Member | 2023-01-02 |
| COHERUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2022-03-14 |
NKT Therapeutics, Inc.
 NKT Therapeutics, Inc. BiotechnologyHealth Technology NKT Therapeutics, Inc. operates as a biotechnology company. It focuses on developing therapeutics based on unique immune cells called natural killer NKT cells. The company was founded by Alem Truneh, S. Brian Wilson, Mark Exley, Steve K. Balk, and Mark A. Tepper on November 20, 2008 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 2012-06-30 |
Osprey Pharmaceuticals Ltd.
 Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Chief Tech/Sci/R&D Officer | 2010-05-31 |
Osprey Pharmaceuticals USA, Inc.
 Osprey Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Osprey Pharmaceuticals USA, Inc. develops protein therapeutics. The firm provides products for the treatment of inflammatory and autoimmune conditions. The company was founded in 2008 and is headquartered in San Francisco, CA | Chief Tech/Sci/R&D Officer | 2010-05-31 |
Training of Barbara Finck
| University of California, Santa Barbara | Undergraduate Degree |
| UCSF School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| FORTE BIOSCIENCES, INC. | Health Technology |
| COMERA LIFE SCIENCES HOLDINGS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
EOS Biotechnology, Inc.
 EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Osprey Pharmaceuticals USA, Inc.
Osprey Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Osprey Pharmaceuticals USA, Inc. develops protein therapeutics. The firm provides products for the treatment of inflammatory and autoimmune conditions. The company was founded in 2008 and is headquartered in San Francisco, CA | Health Technology |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Health Technology |
NKT Therapeutics, Inc.
NKT Therapeutics, Inc. BiotechnologyHealth Technology NKT Therapeutics, Inc. operates as a biotechnology company. It focuses on developing therapeutics based on unique immune cells called natural killer NKT cells. The company was founded by Alem Truneh, S. Brian Wilson, Mark Exley, Steve K. Balk, and Mark A. Tepper on November 20, 2008 and is headquartered in Waltham, MA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Health Technology |
- Stock Market
- Insiders
- Barbara Finck
